Market capitalization | $1.47b |
Enterprise Value | $1.21b |
PER (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 12.17 |
EV/Sales (TTM) EV/Sales | 2.03 |
P/S ratio (TTM) P/S ratio | 2.46 |
P/B ratio (TTM) P/B ratio | 1.58 |
Sales growth (TTM) Sales growth | -10.64% |
Turnover (TTM) Turnover | $597.40m |
As a free StocksGuide basic user, you can view the scores for all 6,953 shares worldwide.
4 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:
4 Analysts have issued a Supernus Pharmaceuticals, Inc. forecast:
Mar '24 |
+/-
%
|
||
Turnover | 597 597 |
11%
11%
|
|
Gross income | 436 436 |
11%
11%
|
|
EBITDA | 91 91 |
31%
31%
|
EBIT (operating result) EBIT | 5.63 5.63 |
88%
88%
|
Net profit | -16 -16 |
130%
130%
|
Figures in millions USD.
If you wish, you can receive an e-mail every morning in time for breakfast containing all the stock news relevant to you.
Supernus Pharmaceuticals, Inc. engages in the development and commercialization of products for the treatment of central nervous system diseases. Its neurology portfolio consists of Oxtellar XR and Trokendi XR, which treats patients with epilepsy. The firm also develops product candidates for the treatment of impulsive aggression and for the treatment of attention deficit hyperactivity disorder. The company was founded by Jack A. Khattar on March 30, 2005 and is headquartered in Rockville, MD.
Head office | United States |
CEO | Jack Khattar |
Employees | 652 |
Founded | 2005 |
Website | www.supernus.com |
StocksGuide is the tool for easily finding, analyzing and monitoring shares. Learn from successful investors and make well-founded investment decisions. We make you a self-determined investor.